ORLANDO — In this exclusive video from Advances in IBD 2018, Miguel Regueiro, MD, chair of the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, discusses the keynote address he gave on how to better understand and monitor safety of IBD medications and biologics.
“We have been talking a lot at AIBD 2018 about these new therapies, biologics, small molecules that impact the immune system and as such, we sometimes will see infections, cancers and my talk is really looking at a practical approach to what do we do when a patient develops an infection, or develops a cancer, or a lymphoma on these medications,” Regueiro, who is also a co-chair of Advances in IBD 2018, told Healio Gastroenterology and Liver Disease.
He said that there were several take-home messages from his keynote that included knowing what types of complications can occur while patients are on their therapies, as well as that a patient does not always need to stop a therapy if a complication occurs.
Regueiro M. Understanding the monitoring and safety of IBD medications and biologics. Presented at: Advances in Inflammatory Bowel Diseases; Dec. 13-15, 2018; Orlando.
Disclosures: Regueiro reports serving as a consultant for AbbVie, Allergan, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres, Takeda and UCB.